VIVOBIOT16.99

Vivo Bio Tech Limited

· Pharma & Health
₹ Crore
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.620.83
Interest Burden (Pretax/EBIT) ×0.340.77
EBIT Margin %26.2825.24
Asset Turnover ×0.330.33
Financial Leverage (Assets/Equity) ×2.481.81
ROE (5-step product) %4.609.67
ROE (reported, avg-equity basis) %4.649.68
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.